Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of EBITDA data on record, last reported at $5.3 million in Q2 2025.

  • For Q2 2025, EBITDA rose 147.88% year-over-year to $5.3 million; the TTM value through May 2025 reached -$17.2 million, down 181.17%, while the annual FY2025 figure was -$17.2 million, 94.99% down from the prior year.
  • EBITDA reached $5.3 million in Q2 2025 per LFCR's latest filing, up from -$9.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $18.6 million in Q2 2021 and bottomed at -$36.5 million in Q1 2023.
  • Average EBITDA over 5 years is -$2.6 million, with a median of -$4.3 million recorded in 2023.
  • Peak YoY movement for EBITDA: soared 4247.22% in 2021, then plummeted 13302.74% in 2022.
  • A 5-year view of EBITDA shows it stood at $7.3 million in 2021, then plummeted by 271.08% to -$12.5 million in 2022, then soared by 213.56% to $14.2 million in 2023, then plummeted by 113.78% to -$2.0 million in 2024, then surged by 371.92% to $5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $5.3 million in Q2 2025, -$9.0 million in Q1 2025, and -$2.0 million in Q4 2024.